AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02086305 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care is the routine practice in the hospital
Study NCT02086305 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Usual care is the routine practice in the hospital
Study NCT01469520 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epivir®, Retrovir® and Viramune®
Description: 12 mL of Epivir® (lamivudine) 10 mg/mL solution plus 24 ml of Retrovir® (zidovudine) 10 mg/mL syrup plus and 20 mL of Viramune® (nevirapine) of 10 mg/mL
Study NCT01469520 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamivudine, Zidovudine and nevirapine
Description: 20 mL of reconstituted granules for suspension containing lamivudine 30mg/zidovudine 60 mg/nevirapine 50 mg per 5 mL of suspension
Study NCT01469520 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamivudine, zidovudine, nevirapine
Description: Lamivudine 30mg/zidovudine 60 mg/nevirapine 50 mg per tablet.
Study NCT03011762 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Computer controlled mandibular positioner
Description: Participants in this arm will complete the computer controlled mandibular positioner test. The study participant, study dentist, and PI are all blinded to the outcome of the CCMP test. Those participants predicted to experience therapeutic success with OAT will have their oral appliance set at the predicted protrusive level; those participants predicted to experience therapeutic failure will have their oral appliance set at a default position. Outcome home sleep tests with the oral appliance in place will be used to determine the accuracy of the prediction.
Study NCT01241604 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BiPAP S/T
Description: Mechanical Non-invasive Ventilation
Study NCT01241604 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BiPAP Auto SV3
Description: Auto Servo Ventilation Device
Study NCT04436770 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-immersive virtual reality therapy
Description: Non-immersive Virtual Reality (VR) therapy exercises, based on assessment, and occupational therapy exercises, for upper extremity or lower extremity.~For the upper extremity, daily, from 20-40 to minutes of VR therapy plus 20-40 minutes of occupational therapy exercises, according to the patient's capacity of VR training, as entire therapy for upper extremity don't exceed 60 minutes.~For the lower extremity, from 20-40 to minutes of VR therapy plus 20-40 minutes of occupational therapy exercises, according to the patient's capacity of VR training, as entire therapy for the lower extremity don't exceed 60 minutes.~The protocol for occupational therapy exercises for the hand included the use of the Canadian plate, thick and thin grip training, lateral and palmar pinch as well as wrist extensor strengthening tasks.~For the ankle and foot, analytical and dexterity exercises using Mirror therapy and alone were used.
Study NCT04436770 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Physiotherapy
Description: Standard physiotherapy program, based on assessment, plus occupational therapy exercises, for upper extremity or lower extremity.~For the upper extremity, daily, 30 minutes of standard physiotherapy plus 30 minutes of occupational therapy exercises.~For the lower extremity, daily, 30 minutes of standard physiotherapy plus 30 minutes of occupational therapy exercises.~The protocol for occupational therapy exercises for the hand included the use of the Canadian plate, thick and thin grip training, lateral and palmar pinch as well as wrist extensor strengthening tasks.~For the ankle and foot, analytical and dexterity exercises were used.
Study NCT03860805 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic tubal ligation
Description: Laparoscopic tubal ligation
Study NCT03860805 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic bilateral salpingectomy
Description: Laparoscopic bilateral salpingectomy
Study NCT04003948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibogaine Hydrochloride
Description: Fixed or ascending doses of ibogaine will be administered for the treatment of opioid withdrawal syndrome.
Study NCT04307134 — intervention group
Intervention type: DRUG
Intervention: Inotuzumab ozogamicin
Description: R/R ALL who treated with Inotuzumab ozogamicin
Study NCT02839031 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT (Cognitive-Behavioral Therapy)
Study NCT02839031 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Control (telephonic support without CBT content)
Study NCT00321906 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: azathioprine
Description: azathioprine 2mg/kg
Study NCT00321906 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sirolimus
Description: sirolimus 2-4mg daily
Study NCT04569604 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MRI scans
Description: Contrast-enhanced, magnetic resonance imaging (MRI) based method to detect disturbances in microvascular flow patterns in the human brain
Study NCT04569604 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Neuro cognitive tests
Description: Standard neuropsychological test battery consists of validated tests to assess cognitive domains including verbal and visual memory, attention, language, visuospatial and executive functioning.
Study NCT04569604 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Questionnaires on Quality of Life
Description: SF36v2, WHO-5 well-being index, HPQ28, Symptom questionnaire, and a general questionnaire on background information, medication and diet.
Study NCT04569604 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood samples
Description: Markers of calcium homeostasis, inflammatory markers and hematology.
Study NCT04569604 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 24 hr urine samples
Description: 24 hr urine content of calcium, phosphate, magnesium, and creatinine.
Study NCT01784926 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Intraocular lens repositioning by scleral suturing
Study NCT01784926 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Intraocular lens exchange with retropupillary iris-claw lens
Study NCT01340729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPI 287
Description: Starting dose of 125 mg/m2 IV via a central venous catheter (CVC) or a peripherally inserted central catheter (PICC) line over 60 minutes (+/- 10 minutes) on Days 1, 8, and 15 (+/- 2 days) of each 28 day (+/- 3 days) study cycle. The 4-week schedule composes one cycle.
Study NCT00845273 — intervention group
Intervention type: DRUG
Intervention: Pegaptanib sodium
Description: Macugen Intravitreous Injection Kit 0.3mg depending on the Investigator prescription.~Frequency and duration are according to Package Insert as follows. Pegaptanib sodium is administered intravitreously once every 6 weeks at a dose level of 0.3 mg (on an oligonucleotide of pegaptanib basis ).
Study NCT01960465 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure
Description: A portable ventilatory assist device, which is the standard first line treatment of sleep apnea.
Study NCT01960465 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous positive airway pressure
Description: A portable ventilatory assist device, which is the standard first line treatment of sleep apnea.
Study NCT02388087 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ROX COUPLER
Description: ROX coupler device is inserted to create an Iliacartero-venous anastamosis following right heart catheterisation.
Study NCT02388087 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Right heart catheterisation and routine care
Description: Participants will have right heart catheterisation followed by routine care. Participants will be blinded to ROX coupler insertion.
Study NCT02927054 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Sepsis Education
Description: Education provided to hospital residents for the recognition and treatment of systemic inflammatory response syndrome (SIRS), sepsis and severe sepsis
Study NCT00558805 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: FISP + Usual Care
Study NCT00558805 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Usual Care
Study NCT03167203 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Embryonic Stem Cell-Derived Retinal Pigment Epithelial Cells
Description: Participants who have received sub-retinal transplant of hESC-RPE cells in an AIRM sponsored clinical trial
Study NCT01720524 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: IV placebo or 0.9% sodium chloride or 10% dextrose. Infusion rate based on weight.
Study NCT01720524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iv sildenafil
Description: loading dose of 0.1 mg/kg over 30 minutes followed by maintenance dose of 0.03 mg/kg/h. To infuse minimum 48 hours and maximum of 14 days.
Study NCT05631145 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MT Combined With XKSA
Description: Morita therapy (MT) comprised bed rest and light work. Xingnao Kaiqiao self-administered acupressure (XKSA) stimulates nine acupoints including Baihui, Sishenchong, Shenmen, Neiguan, Hegu, Taichong, Jianjing, Shenshu, and Yuji.
Study NCT05631145 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: MT
Description: Morita therapy (MT) comprised bed rest and light work.
Study NCT00158262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: Propranolol short-acting or long-acting capsule
Study NCT00158262 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo-matching propranolol short-acting or long-acting capsule
Study NCT03798548 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Bedside CBT
Description: 4 sessions of CBT including psychoeducation about TAVR and how mood can impact recovery in cardiac patients, discussion of patients' expectations and any concerns. Teaching and practice of cognitive restructuring and behavioral goal setting techniques for a healthy recovery.
Study NCT01779063 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: web based multimedia intervention
Description: cognitive therapy based web intervention
Study NCT01779063 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: educational booklet
Description: patient education booklet
Study NCT02959918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEL-212
Description: SEL-212, biologic
Study NCT02959918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEL-037
Description: SEL-037, biologic
Study NCT02959918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SVP-rapamycin (SEL-110)
Description: SVP-rapamycin, biologic
Study NCT02096562 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patients use compression stockings for 10 days after surgery
Description: patients wear compression stocking for 24 hours in the first 2 days after surgery and for at least 8 hours at day 3-10 after surgery
Study NCT02096562 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: normal therapy - no compression stockings
Description: the patients receive the common therapy according to S2 guidelines
Study NCT01149031 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: LOW LEVEL LASER SYSTEM
Description: LASER DIODE CLASS 3B,OMEGA XP
Study NCT02224781 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study NCT01149031 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LOW LEVEL LASER SYSTEM
Description: LASER DIODE CLASS 3B,OMEGA XP
Study NCT04919148 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heat risk and pro-environment behavior message
Description: Eligible participants will be randomized to either a control condition to receive a standardized heat health warning or an intervention condition to receive a heat health warning plus figures depicting heat risk and pro-environment behavior via their preferred and accessible channel (WhatsApp, WeChat or the text message) each time when a Very Hot Weather Warning is issued by the Hong Kong Observatory.
Study NCT01424241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sandostatin LAR
Description: Open label dose escalation of Sandostatin LAR 10 mg, 20 mg, 30 mg, up to 40 mg if necessary.
Study NCT02260219 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Implant of Ahmed Glaucoma Drainage Device, model M4 and S2
Description: Surgically Implant an Ahmed Glaucoma Drainage Device Models S2 and M4, evaluare IOP evolution, complications and need for medication to control IOP
Study NCT03678194 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartphone Support System
Description: 6 weeks smartphone application with daily evaluations
Study NCT03213392 — intervention group
Intervention type: DRUG
Intervention: Anesthetic Agents
Description: four different anesthetic agents will be used during the surgical clipping or coiling of the aneurysm for the maintenance of anesthesia.
Study NCT03836534 — intervention group
Intervention type: BEHAVIORAL
Intervention: adherence to treatment of patients coming out of emergencies
Description: Phone contact of patients within 48 hours of the consultation
Study NCT03190980 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 5% glucose
Description: Neonates will receive 5% glucose, then heel prick wil be performed during which pain will be assessed
Study NCT03190980 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 30% glucose
Description: Neonates will receive 30% glucose, then heel prick wil be performed during which pain will be assessed
Study NCT03190980 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Neonates will receive sterile water, then heel prick wil be performed during which pain will be assessed
Study NCT01150903 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: non-interventional study
Study NCT03173456 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxycodone/APAP
Description: Oxycodone/acetaminophen 5 mg-325 mg oral tablet
Study NCT03173456 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hydrocodone/APAP
Description: Hydrocodone/Acetaminophen 5 Mg-300 Mg oral tablet
Study NCT03173456 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: codeine/APAP
Description: Codeine/acetaminophen 30 mg-300mg oral tablet
Study NCT03173456 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 400 ibuprofen/APAP
Description: ibuprofen/acetaminophen 400 mg-1000mg oral tablet
Study NCT03173456 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 800 ibuprofen/APAP
Description: ibuprofen/acetaminophen 800 mg-1000 mg oral tablet
Study NCT00394888 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: MRI
Description: MRI of the spine.
Study NCT00394888 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: MRI of head and neck
Description: MRI of head and C-spine
Study NCT00394888 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Dermatological Examination
Description: Complete dermatological examination to identify and characterize nature of dermatological anomalies
Study NCT00394888 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Cardiac examination
Description: Complete cardiac examination
Study NCT00394888 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Abdominal ultrasound
Description: Abdominal ultrasound to detect hepatic hemangiomas
Study NCT01651975 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Thickenup
Description: given two 1-cc boluses of liquid contrast agent (barium), one 3-cc of thin liquid contrast, one 3-cc of paste, one cookie with contrast, one 20-cc bolus of liquid contrast, and one 20-cc bolus of thin liquid contrast. The patients are then studied in the anterior/posterior view with one 1-cc, one 3-cc, and one 20-cc bolus of thin liquid barium 1-4. At the end of the protocol patients are routinely administered products with either starch or gel based thickener to evaluate the swallowing safety of the thickened agent. The protocol includes a 3-minute limitation on total fluoroscopy time to ensure clinician and patient safety.
Study NCT01651975 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Thickenup Advance
Description: given two 1-cc boluses of liquid contrast agent (barium), one 3-cc of thin liquid contrast, one 3-cc of paste, one cookie with contrast, one 20-cc bolus of liquid contrast, and one 20-cc bolus of thin liquid contrast. The patients are then studied in the anterior/posterior view with one 1-cc, one 3-cc, and one 20-cc bolus of thin liquid barium 1-4. At the end of the protocol patients are routinely administered products with either starch or gel based thickener to evaluate the swallowing safety of the thickened agent. The protocol includes a 3-minute limitation on total fluoroscopy time to ensure clinician and patient safety.
Study NCT04736069 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical therapy program
Description: In the physical therapy program, 20 minutes of hot pack, 20 minutes of transcutaneous electrical nerve stimulation (TENS; 30 to 40 Hz), 6 minutes of ultrasound (US; 1 MHz, 1 to 1.5 Watt/cm2) therapy were applied to both groups. Both of the programs were supervised by physical therapists. A combined range of motion and strengthening exercises were given to both groups to be performed two times a day.
Study NCT03025269 — intervention group
Intervention type: DRUG
Intervention: Ocrelizumab
Description: This is not a drug intervention study, we are doing an observational study with those who have been prescribed Ocrelizumab by their neurologists during clinical routine appointments
Study NCT04501952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDV
Description: Administered as an intravenous infusion
Study NCT04501952 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Match RDV
Description: Administered as an intravenous infusion
Study NCT00418028 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Study NCT00418028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Study NCT04444765 — intervention group
Intervention type: OTHER
Intervention: Collection of clinical and biological data during renal replacement therapy sessions
Description: Collection of clinical and biological data during renal replacement therapy sessions. Two additional blood samples collected during and after RRT session (critically ill patients all have arterial catheter thus additional samples will not need additional puncture).
Study NCT03965520 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise rehabilitation by near-infrared spectrometer
Description: We adjust exercise intensity by the oxygen saturation change show in near-infrared spectrometer
Study NCT03965520 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: exercise rehabilitation by near-infrared spectrometer
Description: We adjust exercise intensity by the oxygen saturation change show in near-infrared spectrometer
Study NCT04428840 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Self-measurement kiosk
Description: Use of the self-measurement kiosk, with results forwarded to the triage nurse screens
Study NCT03130374 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Olfactory mucosa-derived mesenchymal stem cells
Description: Olfactory mucosa-derived mesenchymal stem cells
Study NCT03104608 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Automatic Self Transcending Meditation
Description: Automatic Self Transcending Meditation is a class of meditation that helps quiet the mind and induces physiological and mental relaxation whilst the eyes are shut. It utilizes a specific sound value (mantra) to draw attention inward and permit the mind to experience a restful but alert state of consciousness. Research suggests that ASTM is easier to learn and to teach in comparison to other meditation techniques. Further, studies have shown that ASTM confers large effect sizes as an anti-depressant.
Study NCT03104608 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Treatment as Usual
Description: Participants randomized to Treatment as Usual (TAU)) will continue to receive their treatment as usual.
Study NCT04235504 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MDI
Description: Subject continues their standard Multiple Daily Injections therapy with FGM or RT-CGM
Study NCT04235504 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AHCL
Description: Subject starts using the Advance Hybrid Close Loop (AHCL) MiniMed™ 670G system version 4.0.~Starting time depends on which Arm the subject is assigned to: if the subject is assigned to the Treatment Arm, then the intervention starts after the RUN-IN period. If the subject is assigned to the Control Arm the intervention will start after 6 months from the date of the enrollment.
Study NCT04235504 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AHCL
Description: Subject starts using the Advance Hybrid Close Loop (AHCL) MiniMed™ 670G system version 4.0.~Starting time depends on which Arm the subject is assigned to: if the subject is assigned to the Treatment Arm, then the intervention starts after the RUN-IN period. If the subject is assigned to the Control Arm the intervention will start after 6 months from the date of the enrollment.
Study NCT01858415 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TriPollar